Viking Therapeutics
VKTX
28.54
+0.16
+0.56%
Viking Therapeutics
US · VKTX
#2352 by market cap
Listed 2015
28.54
+0.16
+0.56%
Live - 5344 symbols - heartbeat 372s ago
· 2026-10-08 07:00
Pre-market
28.50
-0.14%
After-hours
28.62
+0.29%
Overnight
28.41
-0.46%
- Market cap
- 3.59B
- P/E (TTM)i
- -6.11
- P/Bi
- 8.78
- EPSi
- -3.19
- Div yieldi
- 0.00%
- 52W posi
- 16%
Reader sentiment
Are you bullish or bearish on VKTX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 25.67, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Key ratios & quality
- Altman Z-Scorei
- 25.67
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 7.12M | 9.13M | 10.73M | 10.70M | 16.12M | 37.02M | 49.28M | 48.39M |
| Research & development | 19.04M | 23.56M | 31.93M | 44.98M | 54.23M | 63.81M | 101.64M | 344.96M |
| Operating profit | -26.16M | -32.69M | -42.66M | -55.68M | -70.36M | -100.83M | -150.92M | -393.34M |
| Pretax profit | -22.06M | -25.78M | -39.50M | -54.99M | -68.87M | -85.90M | -109.96M | -359.64M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -22.06M | -25.78M | -39.50M | -54.99M | -68.87M | -85.90M | -109.96M | -359.64M |
| Basic EPS | 0 | 0 | -1 | -1 | -1 | -1 | -1 | -3 |
| Diluted EPS | -0.38 | -0.36 | -0.54 | -0.71 | -0.90 | -0.91 | -1.01 | -3.19 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 14.08M | 14.42M | 8.61M | 11.28M | 13.98M | 16.84M |
| Research & development | 41.39M | 60.15M | 89.95M | 153.46M | 150.15M | 115.75M |
| Operating profit | -55.47M | -74.57M | -98.56M | -164.74M | -164.13M | -132.60M |
| Pretax profit | -45.63M | -65.56M | -90.79M | -157.66M | -158.33M | -128.02M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -45.63M | -65.56M | -90.79M | -157.66M | -158.33M | -128.02M |
| Basic EPS | 0 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.41 | -0.58 | -0.81 | -1.38 | -1.37 | -1.10 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 302.13M | 283.50M | 256.10M | 210.53M | 167.04M | 367.23M | 907.22M | 715.60M |
| Cash & ST investments | 301.52M | 275.64M | 248.39M | 202.10M | 155.49M | 362.08M | 902.61M | 705.74M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 302.31M | 284.26M | 256.50M | 210.66M | 168.53M | 368.49M | 908.32M | 715.73M |
| Total current liabilities | 4.55M | 6.78M | 12.13M | 8.78M | 21.95M | 19.14M | 27.41M | 76.67M |
| Short-term debt | -- | 302.00K | 330.00K | 29.00K | 304.00K | 324.00K | 489.00K | 137.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 4,562,000.00 | 7,137,000.00 | 12,158,000.00 | 8,778,000.00 | 23,207,000.00 | 20,071,000.00 | 28,043,000.00 | 76,667,000.00 |
| Total equity | 297.75M | 277.12M | 244.34M | 201.88M | 145.32M | 348.42M | 880.28M | 639.06M |
| Retained earnings | -102.92M | -128.70M | -168.19M | -223.18M | -292.05M | -377.94M | -487.91M | -847.55M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 866.02M | 827.02M | 738.70M | 715.60M | 608.21M | 517.56M |
| Cash & ST investments | 851.86M | 807.72M | 714.57M | 705.74M | 602.96M | 501.66M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 866.99M | 827.85M | 739.42M | 715.73M | 608.24M | 521.90M |
| Total current liabilities | 19.57M | 31.98M | 26.07M | 76.67M | 106.33M | 109.66M |
| Short-term debt | 498.00K | 468.00K | 437.00K | 137.00K | -- | 161.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 20,075,000.00 | 32,390,000.00 | 26,385,000.00 | 76,667,000.00 | 106,325,000.00 | 113,581,000.00 |
| Total equity | 846.92M | 795.46M | 713.03M | 639.06M | 501.92M | 408.32M |
| Retained earnings | -533.54M | -599.10M | -689.88M | -847.55M | -1.01B | -1.13B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -18.76M | -24.75M | -21.78M | -47.59M | -48.40M | -73.38M | -87.79M | -278.69M |
| Depreciation & amortization | 0 | 260.00K | 277.00K | 296.00K | 291.00K | 292.00K | 346.00K | 431.00K |
| Free cash flow | -18.76M | -24.75M | -21.78M | -47.59M | -48.40M | -73.38M | -87.79M | -278.69M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 296.61M | -- | -- | 0 | -6.82M | 269.76M | 597.09M | 0 |
| Ending cash balance | 24.78M | 8.38M | 29.12M | 26.37M | 36.63M | 55.52M | 26.68M | 165.81M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -52.33M | -47.06M | -94.00M | -85.29M | -113.98M | -125.17M |
| Depreciation & amortization | 111.00K | 112.00K | 114.00K | 94.00K | 85.00K | 157.00K |
| Free cash flow | -52.33M | -47.06M | -94.00M | -85.29M | -113.98M | -125.17M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | -- | -- | 0 | 11.63M | -- |
| Ending cash balance | 37.94M | 33.88M | 100.38M | 165.81M | 118.12M | 125.96M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -14.18 | -8.97 | -15.15 | -24.65 | -39.67 | -34.79 | -17.90 | -47.34 |
| ROA %i | -13.60 | -8.79 | -14.61 | -23.54 | -36.32 | -31.99 | -17.22 | -44.29 |
| ROIC %i | -16.00 | -11.40 | -16.36 | -24.94 | -40.40 | -40.65 | -24.52 | -51.74 |
| 5-year avg ROE %i | -- | -- | -81.07 | -50.86 | -20.52 | -24.65 | -26.43 | -32.87 |
| EBIT margin %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 66.40 | 41.83 | 21.12 | 23.98 | 7.61 | 19.19 | 33.09 | 9.33 |
| Quick ratioi | 66.27 | 40.67 | 20.48 | 23.02 | 7.08 | 18.92 | 32.93 | 9.21 |
| Debt / assetsi | 0.00 | 0.23 | 0.14 | 0.01 | 0.93 | 0.34 | 0.12 | 0.02 |
| LT debt / equityi | -- | 0.13 | 0.01 | -- | 0.87 | 0.27 | 0.07 | -- |
| Interest coveragei | -53.61 | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -14.40 | -19.99 | -29.23 | -47.34 | -70.04 | -88.85 |
| ROA %i | -13.98 | -19.33 | -28.31 | -44.29 | -64.04 | -79.24 |
| ROIC %i | -19.33 | -24.77 | -33.80 | -51.74 | -74.43 | -92.65 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 44.25 | 25.86 | 28.34 | 9.33 | 5.72 | 4.72 |
| Quick ratioi | 43.52 | 25.26 | 27.41 | 9.21 | 5.67 | 4.57 |
| Debt / assetsi | 0.12 | 0.11 | 0.10 | 0.02 | 0.00 | 0.78 |
| LT debt / equityi | 0.06 | 0.05 | 0.04 | -- | -- | 0.96 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 07:00:13 · For reference only, not investment advice and not tailored to your situation.